Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cronos GroupFRA:7CI +1.55%87 EV-to-EBIT is -83.74 as of Aug. 13, 2026. GuruFocus rates FRA:7CI with a GF Score™ of 87/100 and a GF Value™ of €3.01 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 681 Drug Manufacturers companies, Cronos Group ranks worse than 146842.73% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Cronos Group's Enterprise Value for the quarter that ended in Jun. 2026 was €262.9 Mil.
Cronos Group's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cronos Group EV-to-EBIT Related Terms
Cronos Group EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Cronos Group's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cronos Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cronos Group EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cronos Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Cronos Group's EV-to-EBIT falls into.
Cronos Group's current Enterprise Value is €368.9 Mil.
Cronos Group's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cronos Group (FRA:7CI) has a EV-to-EBIT of -83.74 as of Aug. 13, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cronos Group and its competitors. According to the industry distribution chart, Cronos Group ranks #999999 out of 681 companies in the Drug Manufacturers industry.
Is Cronos Group's EV-to-EBIT too high?
Cronos Group's current EV-to-EBIT is -83.74. Based on the distribution chart, Cronos Group ranks #999999 out of 681 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cronos Group has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cronos Group's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cronos Group ranks #999999 out of 681 companies for EV-to-EBIT. This places Cronos Group in the lower half of its industry. The industry median EV-to-EBIT is 15.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.76, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cronos Group and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cronos Group's current EV-to-EBIT is -83.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cronos Group stock overvalued right now?
Based on GuruFocus' analysis, Cronos Group (FRA:7CI) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.01, compared to a current price of €2.71 — trading 9.8% below its estimated fair value. The current EV-to-EBIT is -83.74. Cronos Group's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Cronos Group (FRA:7CI), the current EV-to-EBIT is -83.74 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cronos Group (FRA:7CI) Overvalued in 2026?
Based on GuruFocus' analysis, Cronos Group stock appears to be undervalued.
The current stock price of €2.71 is trading 9.8% below its estimated GF Value™ of €3.01.
GuruFocus considers Cronos Group to be Modestly Undervalued.
Key valuation signals for FRA:7CI:
EV-to-EBIT: -83.74
GF Value™: €3.01 vs. price of €2.71 (9.8% below fair value)
No single metric tells the full story. See the FRA:7CI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
87GF Score
Get the complete analysis for FRA:7CI
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7CI has been successfully added to your 
